Shopping Cart 0
Cart Subtotal
AED 0

AMAG Pharmaceuticals Inc (AMAG) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
AED 0

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
AED 0

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
AED 0

Details

Summary

AMAG Pharmaceuticals Inc (AMAG) develops and commercializes specialty pharmaceutical products with focus on maternal health, anemia management and cancer supportive care. It develops and markets products used to reduce the risk of preterm birth in women with a single baby who have a history of singleton spontaneous preterm birth; and products for the treatment of iron deficiency anemia (IDA) in adult patients who have intolerance to oral iron and chronic kidney diseases. AMAG also provides services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units. The company offers its products through a direct sales force and a network of distributors. AMAG is headquartered in Waltham, Massachusetts, the US.

AMAG Pharmaceuticals Inc (AMAG)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

AMAG Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 11

AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 13

Asset Purchase 13

AMAG Pharma Acquires Rights of Orphan Drug Candidate from Velo Bio 13

Private Equity 15

GI Partners Acquires CBR Systems from AMAG Pharma for USD530 Million 15

Licensing Agreements 17

AMAG Pharma and Endoceutics Pharma Enter into Licensing Agreement 17

AMAG Pharma Enters into Licensing Agreement with Palatin Tech 19

Access Pharma Enters Into Licensing Agreement With Amag Pharma For MuGard 21

Equity Offering 22

AMAG Pharma Raises USD230.9 Million in Public Offering of Shares 22

AMAG Pharma Raises USD201 Million in Public Offering of Shares 24

Amag Pharma Files Registration Statement For Public Offering Of Securities For Up To USD 250 Million 26

Debt Offering 27

AMAG Pharma Prices Public Offering of 3.25% Notes Due 2022 for USD300 Million 27

AMAG Pharma Raises USD500 Million in Private Placement of 7.878% Notes Due 2023 29

Amag Pharma Completes Public Offering Of Notes Due 2019 For USD 200 Million 30

Asset Transactions 32

Amag Pharma Plans For Sale Of Drug Manufacturing Facility 32

Acquisition 33

AMAG Pharma Acquires Cord Blood Registry for USD700 Million 33

AMAG Pharma Acquires Lumara Health 35

AMAG Pharmaceuticals Inc-Key Competitors 37

AMAG Pharmaceuticals Inc-Key Employees 38

AMAG Pharmaceuticals Inc-Locations And Subsidiaries 39

Head Office 39

Other Locations & Subsidiaries 39

Recent Developments 40

Financial Announcements 40

Aug 02, 2018: AMAG Pharmaceuticals announces second quarter 2018 financial results and provides corporate update 40

May 03, 2018: AMAG Pharmaceuticals Announces First Quarter 2018 Financial Results and Raises Full Year Financial Guidance 42

Feb 27, 2018: AMAG Reports 2017 Financial Results and Company Update 44

Jan 08, 2018: AMAG Pharmaceuticals Announces Preliminary 2017 Financial Results and Provides 2018 Guidance 46

Nov 02, 2017: AMAG Pharmaceuticals Announces Third Quarter 2017 Financial Results and Business Highlights 48

Aug 03, 2017: AMAG Pharmaceuticals Announces Second Quarter 2017 Financial Results and Provides Corporate Update 51

May 02, 2017: AMAG Pharmaceuticals Announces First Quarter 2017 Financial Results and Provides Corporate Update 55

Feb 14, 2017: AMAG Reports Fourth Quarter and Full Year 2016 Financial Results 57

Jan 09, 2017: AMAG Pharmaceuticals Provides Financial and Business Update 60

Corporate Communications 62

Aug 06, 2018: AMAG Pharmaceuticals Appoints Brian Robinson, M.D. as Senior Vice President of Medical Affairs 62

May 02, 2018: AMAG Pharmaceuticals Appoints J. Alan Butcher as Executive Vice President and Chief Business Officer 63

Sep 29, 2017: AMAG Pharmaceuticals Appoints Tracy Palmer Berns as Chief Compliance Officer 64

Sep 07, 2017: AMAG Pharmaceuticals Appoints Laura Williams, M.D. as Senior Vice President of Clinical Development 65

Apr 25, 2017: AMAG Pharmaceuticals Appoints Arpad Simon, M.D. as Vice President of Pharmacovigilance 66

Mar 06, 2017: AMAG Announces Management Changes and New Commercial Appointments 67

Government and Public Interest 68

Dec 21, 2017: AMAG Pharmaceuticals Awards USD 300,000 in Grants to Further Research in Preterm Birth and Neonatal Health 68

Product News 69

02/02/2017: AMAG Pharmaceuticals Announces Positive Topline Results from Definitive Pharmacokinetic Study for Makena Subcutaneous Administration 69

Product Approvals 70

Jun 26, 2017: AMAG Announces U.S. FDA Filing Acceptance of Supplemental New Drug Application for Makena (hydroxyprogesterone caproate injection) Subcutaneous Auto-Injector 70

Apr 17, 2017: AMAG Submits Supplemental New Drug Application to FDA for Makena (Hydroxyprogesterone Caproate Injection) Auto-Injector for Subcutaneous Use 71

Other Significant Developments 73

Jun 11, 2018: AMAG Pharmaceuticals and March of Dimes Announce Collaboration to Improve Health of Mothers and Babies 73

Nov 08, 2017: AMAG Announces Autologous Cord Blood Cells Improve Motor Function in Some Children with Cerebral Palsy 74

Appendix 75

Methodology 75

About GlobalData 75

Contact Us 75

Disclaimer 75


List Of Figure

List of Figures

AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

AMAG Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 11


List Of Table

List of Tables

AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

AMAG Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9

AMAG Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 11

AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

AMAG Pharma Acquires Rights of Orphan Drug Candidate from Velo Bio 13

GI Partners Acquires CBR Systems from AMAG Pharma for USD530 Million 15

AMAG Pharma and Endoceutics Pharma Enter into Licensing Agreement 17

AMAG Pharma Enters into Licensing Agreement with Palatin Tech 19

Access Pharma Enters Into Licensing Agreement With Amag Pharma For MuGard 21

AMAG Pharma Raises USD230.9 Million in Public Offering of Shares 22

AMAG Pharma Raises USD201 Million in Public Offering of Shares 24

Amag Pharma Files Registration Statement For Public Offering Of Securities For Up To USD 250 Million 26

AMAG Pharma Prices Public Offering of 3.25% Notes Due 2022 for USD300 Million 27

AMAG Pharma Raises USD500 Million in Private Placement of 7.878% Notes Due 2023 29

Amag Pharma Completes Public Offering Of Notes Due 2019 For USD 200 Million 30

Amag Pharma Plans For Sale Of Drug Manufacturing Facility 32

AMAG Pharma Acquires Cord Blood Registry for USD700 Million 33

AMAG Pharma Acquires Lumara Health 35

AMAG Pharmaceuticals Inc, Key Competitors 37

AMAG Pharmaceuticals Inc, Key Employees 38

AMAG Pharmaceuticals Inc, Other Locations 39

AMAG Pharmaceuticals Inc, Subsidiaries 39

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

AMAG Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

AMAG Pharmaceuticals Inc (AMAG) develops and commercializes specialty pharmaceutical products with focus on maternal health, anemia management and cancer supportive care. It develops and markets products used to reduce the risk of preterm birth in women with a single baby who have a history of singleton spontaneous preterm birth; and products for the treatment of iron deficiency anemia (IDA) in adult patients who have intolerance to oral iron and chronic kidney diseases. AMAG also provides services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units. The company offers its products through a direct sales force and a network of distributors. AMAG is headquartered in Waltham, Massachusetts, the US.

AMAG Pharmaceuticals Inc (AMAG)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

AMAG Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 11

AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 13

Asset Purchase 13

AMAG Pharma Acquires Rights of Orphan Drug Candidate from Velo Bio 13

Private Equity 15

GI Partners Acquires CBR Systems from AMAG Pharma for USD530 Million 15

Licensing Agreements 17

AMAG Pharma and Endoceutics Pharma Enter into Licensing Agreement 17

AMAG Pharma Enters into Licensing Agreement with Palatin Tech 19

Access Pharma Enters Into Licensing Agreement With Amag Pharma For MuGard 21

Equity Offering 22

AMAG Pharma Raises USD230.9 Million in Public Offering of Shares 22

AMAG Pharma Raises USD201 Million in Public Offering of Shares 24

Amag Pharma Files Registration Statement For Public Offering Of Securities For Up To USD 250 Million 26

Debt Offering 27

AMAG Pharma Prices Public Offering of 3.25% Notes Due 2022 for USD300 Million 27

AMAG Pharma Raises USD500 Million in Private Placement of 7.878% Notes Due 2023 29

Amag Pharma Completes Public Offering Of Notes Due 2019 For USD 200 Million 30

Asset Transactions 32

Amag Pharma Plans For Sale Of Drug Manufacturing Facility 32

Acquisition 33

AMAG Pharma Acquires Cord Blood Registry for USD700 Million 33

AMAG Pharma Acquires Lumara Health 35

AMAG Pharmaceuticals Inc-Key Competitors 37

AMAG Pharmaceuticals Inc-Key Employees 38

AMAG Pharmaceuticals Inc-Locations And Subsidiaries 39

Head Office 39

Other Locations & Subsidiaries 39

Recent Developments 40

Financial Announcements 40

Aug 02, 2018: AMAG Pharmaceuticals announces second quarter 2018 financial results and provides corporate update 40

May 03, 2018: AMAG Pharmaceuticals Announces First Quarter 2018 Financial Results and Raises Full Year Financial Guidance 42

Feb 27, 2018: AMAG Reports 2017 Financial Results and Company Update 44

Jan 08, 2018: AMAG Pharmaceuticals Announces Preliminary 2017 Financial Results and Provides 2018 Guidance 46

Nov 02, 2017: AMAG Pharmaceuticals Announces Third Quarter 2017 Financial Results and Business Highlights 48

Aug 03, 2017: AMAG Pharmaceuticals Announces Second Quarter 2017 Financial Results and Provides Corporate Update 51

May 02, 2017: AMAG Pharmaceuticals Announces First Quarter 2017 Financial Results and Provides Corporate Update 55

Feb 14, 2017: AMAG Reports Fourth Quarter and Full Year 2016 Financial Results 57

Jan 09, 2017: AMAG Pharmaceuticals Provides Financial and Business Update 60

Corporate Communications 62

Aug 06, 2018: AMAG Pharmaceuticals Appoints Brian Robinson, M.D. as Senior Vice President of Medical Affairs 62

May 02, 2018: AMAG Pharmaceuticals Appoints J. Alan Butcher as Executive Vice President and Chief Business Officer 63

Sep 29, 2017: AMAG Pharmaceuticals Appoints Tracy Palmer Berns as Chief Compliance Officer 64

Sep 07, 2017: AMAG Pharmaceuticals Appoints Laura Williams, M.D. as Senior Vice President of Clinical Development 65

Apr 25, 2017: AMAG Pharmaceuticals Appoints Arpad Simon, M.D. as Vice President of Pharmacovigilance 66

Mar 06, 2017: AMAG Announces Management Changes and New Commercial Appointments 67

Government and Public Interest 68

Dec 21, 2017: AMAG Pharmaceuticals Awards USD 300,000 in Grants to Further Research in Preterm Birth and Neonatal Health 68

Product News 69

02/02/2017: AMAG Pharmaceuticals Announces Positive Topline Results from Definitive Pharmacokinetic Study for Makena Subcutaneous Administration 69

Product Approvals 70

Jun 26, 2017: AMAG Announces U.S. FDA Filing Acceptance of Supplemental New Drug Application for Makena (hydroxyprogesterone caproate injection) Subcutaneous Auto-Injector 70

Apr 17, 2017: AMAG Submits Supplemental New Drug Application to FDA for Makena (Hydroxyprogesterone Caproate Injection) Auto-Injector for Subcutaneous Use 71

Other Significant Developments 73

Jun 11, 2018: AMAG Pharmaceuticals and March of Dimes Announce Collaboration to Improve Health of Mothers and Babies 73

Nov 08, 2017: AMAG Announces Autologous Cord Blood Cells Improve Motor Function in Some Children with Cerebral Palsy 74

Appendix 75

Methodology 75

About GlobalData 75

Contact Us 75

Disclaimer 75


List Of Figure

List of Figures

AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

AMAG Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 11


List Of Table

List of Tables

AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

AMAG Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9

AMAG Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 11

AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

AMAG Pharma Acquires Rights of Orphan Drug Candidate from Velo Bio 13

GI Partners Acquires CBR Systems from AMAG Pharma for USD530 Million 15

AMAG Pharma and Endoceutics Pharma Enter into Licensing Agreement 17

AMAG Pharma Enters into Licensing Agreement with Palatin Tech 19

Access Pharma Enters Into Licensing Agreement With Amag Pharma For MuGard 21

AMAG Pharma Raises USD230.9 Million in Public Offering of Shares 22

AMAG Pharma Raises USD201 Million in Public Offering of Shares 24

Amag Pharma Files Registration Statement For Public Offering Of Securities For Up To USD 250 Million 26

AMAG Pharma Prices Public Offering of 3.25% Notes Due 2022 for USD300 Million 27

AMAG Pharma Raises USD500 Million in Private Placement of 7.878% Notes Due 2023 29

Amag Pharma Completes Public Offering Of Notes Due 2019 For USD 200 Million 30

Amag Pharma Plans For Sale Of Drug Manufacturing Facility 32

AMAG Pharma Acquires Cord Blood Registry for USD700 Million 33

AMAG Pharma Acquires Lumara Health 35

AMAG Pharmaceuticals Inc, Key Competitors 37

AMAG Pharmaceuticals Inc, Key Employees 38

AMAG Pharmaceuticals Inc, Other Locations 39

AMAG Pharmaceuticals Inc, Subsidiaries 39

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

AMAG Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.